Clinical Trials
11
Active:0
Completed:8
Trial Phases
2 Phases
Phase 1:8
Phase 2:3
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (11 trials with phase data)• Click on a phase to view related trials
Phase 1
8 (72.7%)Phase 2
3 (27.3%)The Pharmacokinetics (PK), Safety, Tolerability of SR750 (Prescription F1) in Healthy Volunteers
Phase 1
Not yet recruiting
- Conditions
- Healthy
- Interventions
- Drug: SR750 tabletDrug: Placebo
- First Posted Date
- 2025-04-17
- Last Posted Date
- 2025-04-25
- Lead Sponsor
- Shanghai SIMR Biotechnology Co., Ltd.
- Target Recruit Count
- 40
- Registration Number
- NCT06932536
- Locations
- 🇨🇳
Shanghai Clinical Research Center Phase I Clinical Research Unit (SCRC-PCRU), Shanghai, Shanghai, China
Efficacy and Safety of SR1375 in Adult Patients With CAP
Phase 2
Recruiting
- Conditions
- Community-acquired Pneumonia
- Interventions
- Drug: SR1375 capsule 3mg+regular treatmentsDrug: SR1375 capsule 1mg+regular treatmentsDrug: SR1375 capsule 0.3mg+regular treatmentsDrug: Placebo capsule+regular treatments
- First Posted Date
- 2024-08-29
- Last Posted Date
- 2025-07-09
- Lead Sponsor
- Shanghai SIMR Biotechnology Co., Ltd.
- Target Recruit Count
- 240
- Registration Number
- NCT06577558
- Locations
- 🇨🇳
Gaozhou People's Hospital, Gaozhou, Guangdong, China
🇨🇳The Third Affiliated Hospital of Southern Medical University, Guangzhou, Guangdong, China
🇨🇳Daqing Longnan Hospital, Daqing, Heilongjiang, China
Efficacy, Safety, and Tolerability of SR750 in Patients With Trigeminal Neuralgia
Phase 2
Not yet recruiting
- Conditions
- Trigeminal Neuralgia
- Interventions
- Drug: SR750 tabletDrug: Placebo
- First Posted Date
- 2024-08-26
- Last Posted Date
- 2024-08-26
- Lead Sponsor
- Shanghai SIMR Biotechnology Co., Ltd.
- Target Recruit Count
- 162
- Registration Number
- NCT06571448
The Pharmacokinetics (PK), Safety, Tolerability of SR750 in Healthy Volunteers
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: SR750 tabletDrug: Placebo
- First Posted Date
- 2023-03-03
- Last Posted Date
- 2024-11-28
- Lead Sponsor
- Shanghai SIMR Biotechnology Co., Ltd.
- Target Recruit Count
- 56
- Registration Number
- NCT05753033
- Locations
- 🇨🇳
Shanghai Clinical Research Center Phase I Clinical Research Unit (SCRC-PCRU), Shanghai, China
The Pharmacokinetics (PK), Pharmacodynamics(PD), Safety, Tolerability of SR1375 in Healthy Volunteers
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: SR1375 capsulesOther: Placebo
- First Posted Date
- 2022-06-16
- Last Posted Date
- 2024-11-28
- Lead Sponsor
- Shanghai SIMR Biotechnology Co., Ltd.
- Target Recruit Count
- 32
- Registration Number
- NCT05421923
- Locations
- 🇨🇳
Phase I clinical laboratory of Huashan Hospital, Shanghai, China
- Prev
- 1
- 2
- 3
- Next
News
No news found